GLP-1, GIP and Glucagon: The Three Receptors Retatrutide Targets

Retatrutide is fundamentally a polypharmacology compound—a single molecule designed to bind and activate three distinct G-protein coupled receptors. Understanding each receptor's role is essential to predicting how retatrutide will behave in vivo. Each receptor evolved to respond to specific endogenous hormones (GLP-1, GIP, and glucagon, respectively) under particular metabolic conditions. By creating a synthetic agonist that activates all three, researchers hypothesize they can orchestrate a more comprehensive metabolic response than any single-receptor agonist could achieve.

The GLP-1 receptor is one of the most extensively studied targets in drug development over the past two decades. GLP-1 is secreted by intestinal L-cells in response to glucose and nutrient intake, and it acts as an incretin hormone—meaning it enhances insulin secretion in a glucose-dependent manner. When blood glucose is elevated (postprandially), GLP-1 binds to receptors on pancreatic beta cells and augments insulin release. When glucose is normal or low, GLP-1 does not drive further insulin secretion, making it a glucose-responsive insulin secretagogue rather than a hypoglycemia risk.

Beyond the pancreas, GLP-1 receptors in the brain—particularly in the hypothalamus and nucleus tractus solitarius—mediate appetite suppression and satiety signaling. Activation of these receptors increases the perception of fullness and reduces hunger signals, contributing to decreased food intake. GLP-1 also slows gastric emptying, prolonging the nutrient absorption window and contributing to postprandial glucose control. In adipose tissue, GLP-1 receptor activation appears to affect lipid metabolism and energy expenditure, though this is an area of active investigation. The extensive distribution of GLP-1 receptors and the robust clinical evidence for GLP-1 agonism make this pathway the proven foundation of retatrutide's activity.

GIP, formerly called glucose-dependent insulinotropic polypeptide (previously 'gastric inhibitory peptide'), is secreted by intestinal K-cells alongside GLP-1. Like GLP-1, GIP is a glucose-dependent incretin hormone, enhancing insulin secretion when blood glucose is elevated. For many years, GIP was considered a secondary player in glucose homeostasis, with GLP-1 receiving most research attention. However, recent research has revived interest in GIP, revealing that GIP receptor agonism produces distinct metabolic effects that complement GLP-1 signaling.

GIP receptors are found on pancreatic alpha and beta cells, enteroendocrine cells, and in adipose tissue and other peripheral tissues. GIP agonism enhances glucose-dependent insulin secretion, inhibits glucagon secretion (helping prevent excessive glucose production), and may directly influence lipid metabolism and insulin sensitivity in adipose tissue. Preliminary research in dual-agonist compounds (GLP-1/GIP receptor agonists, such as tirzepatide) suggests that combined GLP-1 and GIP agonism produces greater weight loss and metabolic improvements than GLP-1 monotherapy in some populations. By adding GIP to GLP-1, retatrutide aims to leverage this dual-incretin synergy.

Glucagon is a hormone secreted by pancreatic alpha cells during fasting or hypoglycemia, driving hepatic glucose production to maintain blood glucose. For decades, glucagon's role was viewed primarily through this glucose-regulatory lens. However, physiological and pharmacological research has revealed a more nuanced picture: glucagon receptor signaling also promotes lipolysis (fat breakdown) in adipose tissue, enhances thermogenesis (heat production) in multiple tissues, and increases hepatic ketone production. These effects are metabolically appropriate during fasting or energy deficit, when the body should be mobilizing fat stores and increasing energy expenditure.

Glucagon receptors are highly expressed in liver, but also present in adipose tissue, muscle, and other organs. When activated by glucagon agonists in the postabsorptive state, these receptors enhance metabolic rate and fat oxidation. This is why glucagon receptor agonists are being investigated as standalone agents for weight loss and metabolic disorders. The innovation of retatrutide is combining glucagon agonism with GLP-1 and GIP agonism, so that appetite suppression and glucose control from the incretin pathways occur in concert with the metabolic rate-enhancing and lipolytic effects of glucagon signaling. The challenge is achieving this orchestration safely, without causing inappropriate hyperglycemia or metabolic dysregulation.

Retatrutide is engineered with specific amino acid modifications and structural features that determine its selectivity and potency at each of the three receptors. Unlike natural GLP-1, GIP, and glucagon (which are relatively selective for their cognate receptors), retatrutide must balance activation of all three. The exact affinity and potency ratio—how strongly retatrutide binds and activates each receptor relative to the others—is proprietary information, but it is designed to activate all three receptors at therapeutically relevant concentrations.

In receptor binding assays and cell-based signaling studies, retatrutide demonstrates agonist activity at human GLP-1R, GIP-R, and glucagon-R. The relative potency at each receptor has been characterized in vitro, and in vivo studies (in animals and humans) are designed to correlate these binding properties with physiological outcomes. Understanding the relationship between in vitro receptor potency and in vivo efficacy is a key aspect of early-phase clinical research with retatrutide.

One outstanding question is whether GLP-1, GIP, and glucagon receptor activation in a single molecule produces truly synergistic effects or merely additive ones. Synergy would imply that the three pathways enhance each other's effects—for example, that GLP-1-induced satiety makes the metabolic effects of glucagon agonism more beneficial, or that GIP agonism augments insulin secretion in a way that is greater than GLP-1 alone plus GIP alone. To date, preclinical studies suggest synergy, but the precise mechanisms are not fully elucidated.

Another question concerns tissue-specific receptor interactions. Different tissues have different receptor expression patterns—the pancreatic islet expresses all three receptors, while adipose tissue may have a different profile. How retatrutide's triple agonism is integrated at the tissue level and how this affects systemic metabolic outcomes in humans is still being worked out. Finally, whether the optimal potency ratio among the three receptors is the same for all populations or clinical contexts remains to be determined through large Phase 3 trials and potentially real-world evidence.